NCT07784270ClinicalTrials.gov
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
In breve
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Fase 31500 partecipanti ricercati230 centri16 paesi
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT07784270Apri questa scheda su ClinicalTrials.govSincronizzato 3 settimane fa
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 218 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.
How this score is built
- Enrolment32/40
1,500 participants (target)
- Site count25/25
218 sites
- Country count15/15
16 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
AstraZeneca has led 1,017 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Patologie
- Obesity or Overweight
- Diabetes Mellitus, Type 2
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – Nessun massimo |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 3 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | QUADRUPLE (4) |
| Arruolamento | 1500 partecipanti ricercati |
Sponsor e collaboratori
- AstraZeneca Sponsor
Bracci e interventi
- AZD6234 Dose 1EXPERIMENTAL
AZD6234 Dose 1
- AZD6234 Dose 2EXPERIMENTAL
AZD6234 Dose 2
- PlaceboPLACEBO_COMPARATOR
Matching placebo
Interventi
- Farmaco Lenbelintide
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
- Farmaco Placebo
Placebo matching IMP dose injected subcutaneously, once a week.
Esiti misurati
Esito primario
Percent change in body weight from baseline at 68 weeks of treatment.
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
Orizzonte temporale 68 weeks
Esito secondario
Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on absolute change in weight
Orizzonte temporale 68 weeks
Esito secondario
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%
Orizzonte temporale 68 weeks
Esito secondario
Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%
Orizzonte temporale 68 weeks
Esito secondario
Change in haemoglobin A1C from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 on haemoglobin A1C change
Orizzonte temporale 68 weeks
Esito secondario
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on waist circumference change
Orizzonte temporale 68 weeks
Esito secondario
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change
Orizzonte temporale 68 weeks
Esito secondario
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change
Orizzonte temporale 68 weeks
Esito secondario
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants
Orizzonte temporale 68 weeks
Date
| Data di inizio | 20 agosto 2026 (effettiva) |
|---|---|
| Conclusione primaria | 9 agosto 2028 (stimata) |
| Conclusione | 9 agosto 2028 (stimata) |
| Prima pubblicazione | 25 agosto 2026 (effettiva) |
| Ultimo aggiornamento | 28 ottobre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | ottobre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
58 centri stanno reclutando
Argentina
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Buenos Aires | In reclutamento | |
| Research Site | CABA | In reclutamento | |
| Research Site | Ciudad de Buenos Aires | In reclutamento | |
| Research Site | Mendoza | In reclutamento | |
| Research Site | Ramos Mejía | Non ancora in reclutamento | |
| Research Site | Rosario | In reclutamento | |
| Research Site | San Nicolás | Non ancora in reclutamento |
Australia
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Botany | In reclutamento | |
| Research Site | Camberwell | In reclutamento | |
| Research Site | Charlestown | In reclutamento | |
| Research Site | Helensvale | In reclutamento | |
| Research Site | Maroubra | In reclutamento | |
| Research Site | Waitara | In reclutamento |
Canada
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Calgary | Alberta | In reclutamento |
| Research Site | Hamilton | Ontario | In reclutamento |
| Research Site | Joliette | Quebec | In reclutamento |
| Research Site | Markham | Ontario | In reclutamento |
| Research Site | Moncton | New Brunswick | In reclutamento |
| Research Site | Montreal | Quebec | In reclutamento |
| Research Site | Montreal | Quebec | In reclutamento |
| Research Site | North York | Ontario | In reclutamento |
| Research Site | Québec | Quebec | In reclutamento |
| Research Site | Sarnia | Ontario | In reclutamento |
| Research Site | Scarborough Village | Ontario | In reclutamento |
| Research Site | Stoney Creek | Ontario | Ritirato |
| Research Site | Stouffville | Ontario | In reclutamento |
| Research Site | Toronto | Ontario | In reclutamento |
| Research Site | Toronto | Ontario | In reclutamento |
| Research Site | Trois-Rivières | Quebec | In reclutamento |
| Research Site | Truro | Nova Scotia | In reclutamento |
| Research Site | Vancouver | British Columbia | In reclutamento |
Chile
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Concepción | Non ancora in reclutamento | |
| Research Site | Concepción | Non ancora in reclutamento | |
| Research Site | Concepción | Non ancora in reclutamento | |
| Research Site | Iquique | Non ancora in reclutamento | |
| Research Site | Las Condes | Non ancora in reclutamento | |
| Research Site | Providencia | Non ancora in reclutamento | |
| Research Site | Santiago | Non ancora in reclutamento | |
| Research Site | Santiago | Non ancora in reclutamento | |
| Research Site | Santiago | Non ancora in reclutamento |
China
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Beijing | Non ancora in reclutamento | |
| Research Site | Cangzhou | Non ancora in reclutamento | |
| Research Site | Changchun | Non ancora in reclutamento | |
| Research Site | Chengdu | Non ancora in reclutamento | |
| Research Site | Chengdu | Non ancora in reclutamento | |
| Research Site | Danyang | Non ancora in reclutamento | |
| Research Site | Ganzhou | Non ancora in reclutamento | |
| Research Site | Guangzhou | Non ancora in reclutamento | |
| Research Site | Huizhou | Non ancora in reclutamento | |
| Research Site | Huzhou | Non ancora in reclutamento |
Nella scheda del registro sono indicati altri 180 centri.
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 28 ottobre 2026
Data di conclusione posticipata
Primary completion delayed 1 days
2028-08-082028-08-09
- 28 ottobre 2026
Centro aggiunto
3 sites added (230 total)
227230
- 22 settembre 2026
Stato modificato
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 22 settembre 2026
Reclutamento aperto
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 22 settembre 2026
Data di conclusione anticipata
Primary completion advanced 1 days
2028-08-092028-08-08
- 22 settembre 2026
Centro aggiunto
9 sites added (227 total)
218227